New drug shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT05900206
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study compares a newer targeted drug, trastuzumab deruxtecan (T-DXd), with standard chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. About 370 adults with large or lymph node-positive tumors will receive either T-DXd or standard treatment for three cycles, then further treatment based on tumor biology. The main goal is to see if T-DXd leads to a higher rate of complete tumor disappearance at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital
RECRUITINGStockholm, 17164, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Norrlands University Hospital
NOT_YET_RECRUITINGUmeå, 90185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sankt Gorans Hospital
NOT_YET_RECRUITINGStockholm, 11219, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Skåne University Hospital
NOT_YET_RECRUITINGMalmö, 21428, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stockholm Southern Hospital
NOT_YET_RECRUITINGStockholm, 11861, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Uppsala University Hospital
NOT_YET_RECRUITINGUppsala, 75185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Örebro University Hospital
NOT_YET_RECRUITINGÖrebro, 70185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to
If successful, this could lead to a more effective pre-surgery treatment for HER2-positive breast cancer, potentially improving cure rates and reducing the need for chemotherapy.
What could go wrong
This is a phase 2 trial with 370 participants, so results are preliminary. The new drug may not be more effective than standard care, and side effects like lung inflammation or heart problems are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.